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ABSTRACT 
 
 
 
Background: The reproducibility of cardiopulmonary exercise testing (CPET) has not been 
established in young cystic fibrosis (CF) patients using a valid protocol. 
 
Methods: Thirteen 7-18 year olds completed three CPETs, separated by 48 h and 4-6 weeks. 
CPET involved a ramp-incremental cycling test with supramaximal verification.  
 
Results: Maximal oxygen uptake was repeatedly determined with no learning effect and 
typical errors expressed as a coefficient of variation (TECV%) of 9.3% (48 h) and 13.3% (4-6 
weeks). The reproducibility of additional parameters of aerobic function [gas exchange 
threshold (TECV%: 11.2%, 16.8%); V̇O2 mean response time (TECV%: 37.8%, 89.4%); V̇O2 
gain (TECV%: 17.4%, 24.5%)] and clinical utility [e.g. SpO2% (TECV%: 2.2%, 3.1%); 
ventilatory drive (V̇E/V̇CO2-slope) (TECV%: 7.8%, 17.7%)] was also established over the short- 
and medium-term, respectively. 
 
Conclusion: These results establish limits of variability to determine meaningful changes 
over the short- and medium-term for CPET outcomes in young CF patients.  
 
 
 
Keywords: Cystic fibrosis; exercise testing; maximal oxygen uptake; cardiorespiratory 
fitness; reproducibility. 
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INTRODUCTION  
A cardiopulmonary exercise test (CPET) is considered the ‘gold-standard’ method for 
evaluating aerobic fitness [maximal oxygen uptake (V̇O2max)] in patients with mild-to-
moderate cystic fibrosis (CF). The European CF Society (ECFS) Exercise Working Group 
recently promoted CPET as the exercise testing method of choice for this patient group. 
Moreover, the ECFS Clinical Trials Network Standardisation Committee has called for 
assessment of the validity, reproducibility and feasibility of outcome measures utilised in CF 
and advocated research into the most appropriate exercise test for paediatric patients[1]. 
Recently, our research group presented a combined incremental and supramaximal 
(Smax) verification CPET protocol, which is superior at determining valid V̇O2max in young CF 
patients compared to a ramp only protocol[2]. V̇O2max is currently the principle outcome from 
a CPET, as it has been shown to be an independent predictor of CF patient mortality[3]. 
However, a more comprehensive evaluation of patients’ cardiorespiratory fitness may be 
gained from CPET, through the quantification of submaximal parameters of aerobic (lactate 
threshold (LT), the kinetics of V̇O2 and work efficiency) and ventilatory (V̇E/V̇CO2-slope and 
oxygen uptake efficiency slope (OUES)[4]) function. Submaximal outcomes may be 
especially useful in the clinical environment, as patients may not be able or willing to provide 
a maximal effort.  
Unfortunately, insufficient data exists regarding the reproducibility of CPET in CF 
patients and that which does exist has utilised testing protocols which cannot verify a ‘true’ 
maximal effort[e.g.5,6]. Moreover, the only paediatric study to address this issue[5] did not 
measure V̇O2max. Quantifying reproducibility enables researchers and clinicians to understand 
the variation associated with outcome measures[7] and to determine meaningful changes[8]. 
Consequently, inferences regarding therapeutic interventions or disease-related changes in 
CPET derived parameters cannot currently be discerned with certainty in these patients. 
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Therefore, this study sought to establish the short- (48 h) and medium-term (4-6 weeks) 
reproducibility of maximal and submaximal indicators of cardiorespiratory fitness using our 
recently validated CPET protocol.  
 
MATERIAL and METHODS  
Study population. Thirteen young patients (Table 1) with mild-to-moderate CF were 
recruited from outpatient CF clinics at the Royal Devon and Exeter NHS Foundation Trust 
Hospital (RD&E). Inclusion criteria comprised a CF diagnosis based on clinical features, 
sweat chloride > 60 mmol·L
-1
 / 100 mg and genotyping. Stable lung function within 10% of 
best in the preceding 6 months and no increase in symptoms or weight loss 2 weeks prior to 
testing was obligatory. Unstable non-pulmonary comorbidities or acute infections warranted 
exclusion. Disease severity was graded using the Schwachman score[9] and routine clinical 
measurements obtained as part of patients’ annual review by their multidisciplinary CF 
clinical care team (Table 1). Ethics approval was granted by the South West NHS Research 
Ethics Committee and written informed consent and assent obtained from parents/guardians 
and patients, respectively. Patients arrived at the laboratory in a rested state, at least 2 h post-
prandial and having refrained from caffeine for > 2 h. All patients were instructed to continue 
maintenance medications as usual throughout the duration of their study involvement.  
 
Anthropometry and pulmonary function. Body mass (Seca 220; Vogel & Halke, 
Hamburg, Germany) and stature (Seca 220; Vogel & Halke, Hamburg, Germany) were 
measured to the nearest 0.01 kg and 0.01 m, respectively, at each visit. Skin folds were 
measured to the nearest 1 mm on the right-hand side of the body at the biceps brachii, tricep, 
subscapula and suprailiac regions (Harpenden; British Indicators, Burgess Hill, UK). Forced 
vital capacity (FVC) and forced expiratory volume in 1-s (FEV1) were also assessed at each 
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visit to the laboratory, using flow-volume loop spirometry (MicroMedical MicroLoop 3535, 
Numed, Sheffield, UK). The best of three consistent exhalations (< 5% variability) was 
recorded, in accordance with the British Thoracic Society (1994) guidelines. All lung 
function measurements were expressed as a percentage predicted normal, using appropriate 
reference data[10]. 
 
Exercise testing protocol. Following familiarisation, exercise was performed on a cycle 
ergometer [Lode Excalibur or Lode Corival, Groningen, The Netherlands]. The experimental 
protocol was identical to our previous study[2], using combined exhaustive ramp-incremental 
and Smax verification tests. Following 3-min warm-up (20 W), patients completed an 
incremental ramp cycling test, whereby resistance increased at a predetermined rate (10-25 
W·min
-1). Ramp rate was dependent on patients’ age, height and fitness level, to elicit ~8-12 
minute test durations. Patients maintained ~70-80 rpm until volitional exhaustion, defined as 
a drop in cadence > 10 rpm for 5 consecutive seconds despite strong verbal encouragement. 
Five minutes active (20 W cycling) and 10-min passive seated recovery followed. Smax 
verification of V̇O2max was then performed, whereby 3-min warm-up (20 W) preceded a ‘step’ 
transition to a constant work rate equivalent to 110% peak power output. This work rate was 
maintained until voluntary exhaustion. Five minutes active recovery (20 W cycling) 
completed the CPET.  
 Following test one (T1), all procedures were repeated 48 h (short-term; T2) and 4-6 
weeks (medium-term; T3) later, at a similar time of day. Medium-term clinical stability was 
monitored T1-T3, with disease considered unstable if a pulmonary exacerbation developed, a 
change in pulmonary medications was required, chest signs on physical examination altered, 
or a ≥10% decline in pulmonary function was recorded.   
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Experimental measures. Gas analysis. Prior to each test, the metabolic cart (Metalyzer 3B 
Cortex, Biophysik, Leipzig, Germany) was calibrated using gases of known concentration, 
and the turbine volume transducer using a 3 L calibration syringe (Hans Rudolph, Kansas 
City, MO). Breath-by-breath pulmonary gas exchange and ventilation were measured and 
averaged to 15-s time bins.  The highest 15-s stationary average V̇O2 from the ramp and Smax 
protocols[2] represented V̇O2max.  
   
Submaximal gas exchange parameters. The LT was non-invasively identified using the gas 
exchange threshold (GET)[11] and confirmed through visual inspection of the ventilatory 
equivalents for V̇O2 and V̇CO2[12]. The V̇O2 mean response time (MRT) was determined using 
the time from the onset of the ramp test to the intersection point between the baseline V̇O2 and 
a backwards extrapolation of the slope of V̇O2 as a function of time. The V̇O2 ‘gain’ (ΔV̇O2/Δ 
WR) was determined by regression of the ‘linear’ portion of the V̇O2 response against power 
output. The OUES for the entire exercise duration (OUES100) and up to the GET (OUESGET) 
were derived from the slope of the linear function between V̇O2 (mL∙min
-1
) and log V̇E (L∙min
-
1
)[4]. The V̇E/V̇CO2–slope (ventilatory drive) was calculated using linear regression during the 
entire CPET[13].  
 
Additional measures: Heart rate (HR) was determined every 5-s (PhysioFlow, PF-05, 
Manatec Biomedical, Paris, France), with the highest 15-s value taken as peak HR (HRpeak). 
Fingertip arterial O2 saturation (SpO2%) was measured on a beat-by-beat basis via pulse 
oximetry (NONIN, Avant 4000, NONIN Medical Inc., USA). Subjective ratings of perceived 
exertion (RPE) and dyspnoea (RPD) were recorded upon exhaustion using the pictorial 
children’s effort rating table (P-CERT) and the 0-10 category ratio (CR-10) scale, 
respectively, the methodology for which is described elsewhere[2]. 
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Analysis. Data are expressed as means and standard deviations unless otherwise stated. 
Reproducibility was assessed using a downloadable spreadsheet[14]. Following initial 
analyses to ensure distribution normality and heteroscedasticity, paired samples t-tests 
examined differences between tests with significance set at p < 0.05. Change in the mean, 
intraclass correlation coefficients (ICCs), absolute typical error (TE) and TE expressed as a 
percentage of the coefficient of variation (TECV%), were calculated (with 90% confidence 
limits) for short- (T1-T2) and medium-term (T1-T3) pairwise comparisons.  
  
RESULTS 
One patient was lost to follow-up at T3, due to reasons unrelated to the study. Table 1 
summarises patients’ (n=13) baseline physical characteristics. Clinical stability was defined 
by symptoms, changes in patients’ treatment, spirometric variables and body mass over the 
course of the study (T1-T3). All patients remained clinically stable and with no change in 
symptoms, treatment, body mass [50.89 (17.26) vs. 50.98 (17.17) kg; p = 0.63], BMI [21.23 
(7.79) vs. 21.18 (7.61) kg·m
2
; p = 0.97] or lung function [FVC: 3.12 (1.08) vs. 3.03 (1.04) L; 
p = 0.10; FEV1: 2.53 (0.88) vs. 2.48 (0.87) L; p = 0.10]. Stability predated T1 (i.e. 
recruitment) and was maintained beyond T3.  
 Maximal and submaximal physiological responses from the CPET are presented in 
Table 2. Short- (T1-T2) and medium-term (T1-T3) reproducibility data from CPET derived 
measures are presented in Tables 3 and 4 respectively. The reproducibility for V̇O2max is 
presented in Figure 1. The GET and OUESGET were identifiable in all patients at T1 and 12 
(92%) patients at T2 and T3. MRT was detected in 11 (85%) patients from T1-T3. 
 When compared with this combined approach (ramp and Smax), V̇O2max obtained using 
the traditional ramp only method was significantly lower at both T2 [1.76 (0.56) vs. 1.63 
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(0.52) L·min
-1
; p = 0.01] and T3 [1.69 (0.55) vs. 1.62 (0.54) L·min
-1
; p = 0.07], with a trend 
towards significance at T1 [1.77 (0.57 vs. 1.68 (0.56) L·min
-1
; p = 0.07], as has been 
previously demonstrated[2]. Moreover, V̇O2max using the combined approach was also 
associated with smaller error over both the short- [TE: 0.15 (0.12-0.23) vs. 0.23 (0.17-0.38) 
L·min
-1
; TECV%: 9.3 (6.9-14.3) vs. 13.5 (9.5-23.3) %] and medium-term [TE: 0.16 (0.12-0.25) 
vs. 0.19 (0.14-0.32) L·min
-1
; TECV%: 13.3 (9.9-20.9) vs. 15.5 (10.9-26.9) %] when compared 
with a ramp test in isolation. 
 
DISCUSSION 
The principle finding of this study was that CPET was reproducible when determining 
V̇O2max [short-term (T1-T2) ICC: 0.94; medium-term (T1-T3) ICC: 0.93], with no significant 
learning effect and short- and medium-term TEs of 150 mL (Δ9%) and 160 mL (Δ13.3%). Of 
the additional maximal parameters, HR (3.2%, 7.8%), SaO2% (2.2%, 3.1%) and RPE (7.8%, 
7.6%) appear to hold acceptable short- and medium-term reproducibility, respectively. 
Submaximal measures were identifiable in most cases, with the V̇E/V̇CO2-slope (7.8%), 
V̇E/V̇CO2 at the GET (8.8%), V̇E/V̇O2 at the GET (10.2%), the GET (11.2%) and OUES100 
(12.0%) demonstrating promising reproducibility over 48 h. However, an increased TEcv% 
was observed for submaximal parameters at 4-6 weeks, with three (V̇O2 gain, OUESGET, V̇O2 
MRT) TEs increasing above 20% (24.5%, 45.4%, 89.0%, respectively). Excluding the latter 
two variables (OUESGET and V̇O2 MRT), good short- and medium-term agreement was 
observed for all measures, highlighting the potential for CPET outcomes to be used to 
monitor disease progression and/or the effect of therapeutic interventions. 
Our data contribute significantly to the literature because the reproducibility of V̇O2max 
has not been established in CF using a valid protocol. Reproducibility over time is crucial 
when evaluating the efficacy of treatments (e.g. antimicrobials, mucolytics and gene mutation 
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targeted therapies) which may accrue over weeks or months, as well as monitoring exercise 
training interventions (4-6 weeks). To our knowledge, only one study has examined the 
reproducibility of Smax verified (treadmill) V̇O2peak in a paediatric clinical population[15], 
reporting an 8.2% (100 mL) variation in young spina bifida patients over a 2 week period. 
Using a solitary traditional ramp test, variations of 6.9%[6] and 8.5%[16] have been reported 
over 4 weeks in CF adults for V̇O2peak. The reproducibility estimate for V̇O2max in the present 
study is therefore similar (9.3% and 13.3%) to these earlier studies[6,16] and confirms CPET 
as a reproducible assessment tool. Whilst the compromised validity of performing traditional 
ramp tests, such as the popular Gofrey protocol, in isolation has previously been 
demonstrated[2] and substantiated herein, the present study in paediatric CF patients also 
highlights a larger within-subject variation in V̇O2max over both the short- (13.5 vs. 9.3 %) and 
medium-term (15.5 vs. 13.3 %) when compared with the combined ramp and Smax approach. 
Only one study[5] has previously investigated CPET reproducibility in CF children, but is 
limited due to methodological concerns. Firstly, only three outcome measures (peak power 
output, SaO2% and HR) were obtained, offering limited interpretation of aerobic fitness. 
Moreover, an intermittent sprint cycle test preceded the ramp test, which likely caused fatigue 
and may explain, in part, their low ramp test duration (~4 min).  
Outcome measures which can assess patients’ ability to perform at intensities similar 
to activities of daily living are also important. Submaximal measures hold specific value 
when maximal exercise performance is limited by ventilatory capacity and/or effort[2,4]. 
Furthermore, the GET can improve independent of V̇O2max[e.g.12,17] and facilitates the 
identification of individualised exercise intensities within specific intensity domains (i.e. at a 
%GET or %Δ) for young CF patients[e.g.18]. The present study employed a cluster of 
measures and two independent observers to identify the GET in 12 of 13 (92%) patients for 
all tests, with TE of 11.2% (or 110 mL) and 16.8% (or 140 mL) over the short- and medium-
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term, respectively. Using similar methodology, our laboratory has previously reported a 
similar GET detection rate (100%) in healthy children, with a reproducibility estimate of 
~8%[19]. The present findings challenge previous reports suggesting difficulties in non-
invasively detecting the GET and ventilatory threshold in patients with chronic respiratory 
disease and airflow limitation[e.g.20], likely due to the mild disease severity and 
subsequently normal ventilatory drive of our patients. The V̇O2 gain was associated with 
reasonable TE of 17.4% and 24.5% over the short- and medium-term, respectively. The V̇O2 
MRT was associated with considerably greater short- (37.8%) and medium-term (89.4%) 
variation. These submaximal measures, especially the MRT, may therefore be less useful 
than the GET.  
Ventilatory efficiency is best described by relating V̇O2 and V̇CO2 dynamics to 
V̇E[21]. The V̇E-V̇O2 relationship is optimally described through the OUES[21], which is 
theoretically resistant to early test termination and intra- and inter-observed variability[22]. In 
the current study, OUES100 was detectable in all tests and the OUESGET detectable in all 
patients at T1 and 92% at T2 and T3. Short- and medium-term TEs of 12.0% and 15.3% were 
associated with the OUES100, compared with 8.3% documented in adult CF patients over a 4 
week period[16]. Similar variations of 7.8% and 17.7% were documented for the V̇E/V̇CO2-
slope in the present study. As the OUESGET was associated with increased short- (17.9%) and 
medium-term (45.4%) error and lower detection rate compared to the OUES100, the OUES100 
appears a more robust outcome measure.  
The present study provides the reproducibility for maximal and submaximal 
parameters over the short- and medium-term. Our data denote that V̇O2max changes exceeding 
9% (150 mL) and 13% (160 mL) may indicate a change attributable to therapeutic 
intervention or disease progression over the short- and medium-term, respectively. The TE 
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must, however, be considered relative to an established smallest worthwhile change (SWC), 
to estimate how many participants are needed to observe a ‘meaningful’ effect[7,8,24]. 
Using Hopkins’ formula[7] for the estimation of sample size [n=8(CV2/d2)], CV and d 
can be substituted for TE and SWC, respectively. While the present study has documented 
the CV, the value of d is uncertain for CPET outcomes in CF. Cox and Elkins[23] recently 
raised concerns regarding how ‘clinically worthwhile’ exercise training interventions are for 
patients with CF, given that the SWC for outcome measures had yet to be established. 
However, the mean annual rate of V̇O2max decline could, for example, be used to determine 
the SWC in V̇O2max, since it reportedly predicts CF patient survival[29]. Using Pianosi and 
colleagues’[29] annual V̇O2max decline and the fitness of our similarly aged patients, a ~6% 
increase in V̇O2max relative to baseline fitness would be required to prevent a meaningful drop 
in prognostic stratification. Using 6% as the SWC and a 13.3% TE, 5 patients would be 
required to detect a change in V̇O2max from a 4-6 week intervention that would be considered 
meaningful and clinically worthwhile. 
Determining the extent to which changes in outcome measurements relate to a given 
reference measure is essential to the clinical utility of CPET. Responsiveness to intervention 
has been conceptually described as a signal-to-noise ratio[7,8,24], whereby the TE represents 
the ‘noise’ and any intervention-induced effect, the ‘signal’. Data concerning V̇O2max 
responsiveness within CF are sparse[26]. Of the available evidence, studies have reported 
training-related improvements in V̇O2max ranging from ~10-20%[e.g.26,27,28]. Using our 
established long-term TE, the aerobic training improvement could be considered meaningful 
with a signal-to-noise ratio of ~1.5:1.0 for a ~20% improvement, but questionable, with a 
signal to noise ratio of ~0.8:1.0 for a 10% improvement. Unfortunately, the signal-to-noise 
ratio for most parameters is unknown. If future intervention studies provided more 
comprehensive CPET data, this would permit more informed data interpretation, as 
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researchers could select measurements with higher signal-to-noise ratios, whilst also 
considering their sensitivity.  
 Standardising CPET procedures will enable a larger empirical database of CF patients 
to accumulate and, longitudinally, enhance our understanding of the link between 
physiological dysfunction during exercise and patients’ prognostic stratification. Whilst 
V̇O2peak possesses recognised prognostic value[3], the V̇E/V̇CO2-slope and OUES have 
demonstrated superior prognostic information in other clinical populations[e.g.21,30] and 
warrant investigation in CF, particularly given that although patients remained clinically 
stable throughout the present study, increased medium-term noise was associated with 
submaximal parameters. This may indicate value in detecting subtle clinical changes, which 
current clinical assessments cannot. CPET to assess therapeutic interventions also requires 
investigation.  
In conclusion, V̇O2max was reproducible over 48-h (Δ150 mL; Δ9.3%) and 4-6 wks 
(Δ160 mL; Δ13.3%). Supplementary maximal and submaximal parameters should be 
incorporated to comprehensively assess aerobic function. The present study provides a 
reproducible CPET protocol for young patients with mild-to-moderate CF and will inform 
sample size and power calculations when planning interventional studies that use 
cardiorespiratory fitness as an endpoint.  
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FIGURE LEGENDS  
 
 
Figure 1. Line of identity plot for V̇O2max over both the short- [48 h (1a)] and medium-term 
[4-6 weeks (1b)].   
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Figure 1.  
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TABLES 
 
 
 
 
Table 1. Patients’ baseline anthropometric and pulmonary function data upon initiation into 
the study (n = 13; 4 females). 
 
 
Variable Value (mean ± SD)  Range 
Age (years)   12.81 ± 3.26  7.57-18.44 
Stature (m)  1.53 ± 0.16  1.23-1.74 
Body mass (kg) 50.89 ± 17.26  24.35-83.50 
BMI (kg·m
2
)   21.18 ± 3.86  14.19-28.24 
SSkF (mm) 43 ± 13  24-67 
Gender m = 9, f = 4 - 
CFTR genotype: 
Homozygote ∆F508  
∆F508/P67L 
∆F508/ 621+IG     T 
∆F508/ 2184delA 
∆F508/ G55ID 
- 
9 
1 
1 
1 
1 
- 
- 
- 
- 
- 
- 
Chronic P. Aeruginosa infection
 a “chronic,” n = 2;  
“intermittent,” n = 4  
“free,” n = 5 
“never,” n = 2 
Shwachman score 82 ± 6 67-91 
Northern score
 b 
4 ± 1  2-6 
FVC [ % predicted (L)] 103.5 ± 15.0 (3.3 ± 1.2) 79.0-127.0 (1.6-5.1) 
FEV1 [% predicted (L)] 91.7 ± 17.8 (2.7 ± 1.0) 65.0-120.0 (1.4-4.1) 
   
 
Values are means ± SD, with the range also displayed where suitable, unless otherwise stated. 
BMI, body mass index; SSkF, sum of skinfolds; CFTR, cystic fibrosis transmembrane conductance regulator; P. 
Aeruginosa; Pseudomonas Aeruginosa; Shwachman score - scoring 4 separate aspects of the disease profile; 
general activity; physical examination; nutritional status; and chest radiographic findings, using the most recent 
clinical review information. A total of 100 points represents a perfect score of health; FVC, forced vital 
capacity; FEV1, forced expiratory volume in 1 second; 
a
 According to Leeds Criteria, “chronic”, >50% of the 
preceding 12 months were P. aeruginosa culture positive; “intermittent”, ≤50% of the preceding 12 months 
were P. aeruginosa culture positive; “never”, no growth of P. aeruginosa for the previous 12 months, having 
previously been P. aeruginosa culture positive; “free”, P. aeruginosa has never been cultured.   
b
 Provides evidence of radiographic chest findings. Maximum score is 20, with 20 being the most severe.  
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Table 2. Patients’ physiological responses to CPET during the three visits. 
 
 
 
 
 
 
 
 
Variable n Test 1  Test 2  Test 3  
Maximal exercise 
parameters 
- - - - 
V̇O2max (L∙min
-1
) 13 1.77 (0.57) 1.76 (0.56) 1.68 (0.55) 
HRpeak (b∙min
-1
) 11 190 (12) 186 (14) 186 (19) 
SpO2 (%) 13 95 (3) 96 (1) 96 (3) 
RPE 13 9 (2) 9 (2) 9 (1) 
RPD 13 7 (3) 6 (3) 8 (3) 
Ramp peak power output 
(W) 
13 157 (55) 148 (62) 145 (65) 
Submaximal parameters - - - - 
GET (L∙min-1) 12 1.00 (0.22) 0.93 (0.21) 1.05 (0.29) 
MRT (s) 11 42 (15) 65 (17) 54 (26) 
V̇O2 gain (mL·min
-1
·W
-1
)  12 8.01 (1.36) 8.11 (1.22) 7.73 (2.64) 
OUES100 (mL·min
-1
·logL
-1
) 12 803 (227) 789 (181) 799 (218) 
OUESGET (mL·min
-1
·logL
-1
) 12 797 (223) 730 (188) 756 (389) 
V̇E/V̇CO2-slope 12 34.13 (4.51) 33.26 (3.25) 32.14 (5.39) 
V̇E/V̇O2 at the GET 12 28.57 (5.45) 28.63 (3.84) 28.09 (4.58) 
V̇E/V̇CO2 at the GET  12 28.07 (3.96) 29.15 (5.43) 27.95 (5.51) 
     
 
Values are means ± SD, with the range also displayed unless otherwise stated.  
V̇O2max, maximal oxygen uptake; HRpeak, peak heart rate; SpO2%, end-exercise arterial oxygen saturation; RPE, 
end-exercise rating of perceived exertion; RPD, end-exercise rating of perceived dyspnoea; ramp; incremental 
ramp test; GET, non-invasive estimate of the lactate threshold which was verified by the ventilatory threshold; 
MRT, mean response time; V̇O2 gain, oxygen cost of exercise; OUES100, oxygen uptake efficiency slope for the 
entire duration of the ramp test; OUESGET, OUES to the GET; V̇E/V̇CO2-slope, ventilatory drive; V̇E/V̇O2, 
ventilatory equivalent for oxygen uptake; V̇E/V̇CO2, ventilatory equivalent for carbon dioxide.    
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Table 3. Short-term (48 h) test-retest reproducibility (T1-T2) of CPET derived measures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are reported as means (95% confidence limits). TE, typical error; TECV%, TE expressed as a percentage of the coefficient of variation; ICC, intra-class correlation 
coefficient. See table 2 for list of abbreviations for exercise outcomes.   
 
 
Variable N Change in 
the mean 
p-value TE (90% CL) TECV% (90% CL) ICC p-value 
Lung function - - - - - - - 
FVC (L) 13 0.01 0.79 0.08 (0.05-0.11) 3.1 (2.3-4.7) 1.00 <0.01 
FEV1 (L) 13 -0.02 0.48 0.07 (0.06-0.11) 2.7 (2.0-4.1) 0.99 <0.01 
Maximal exercise parameters - - - - - - - 
V̇O2max (L∙min
-1
) 13 -0.01    0.91 0.15 (0.12-0.23) 9.3 (6.9-14.3) 0.94 <0.01 
HRpeak (b∙min
-1
) 11 -4    0.14 6 (4-9) 3.2 (2.3-5.1) 0.83 <0.01 
SpO2 (%) 13 1    0.42 2 (2-3) 2.2 (1.7-3.4) 0.03   0.91 
RPE 13 0.1    0.72 0.5 (0.4-0.8) 7.8 (5.8-12.0) 0.91 <0.01 
RPD 13 -1.3    0.09 1.7 (1.3-2.6) 63.7 (45.1-111.0) 0.60   0.05 
Ramp peak power output (W) 13 -9    0.11 14 (11.21) 21.6 (16.0-34.6) 0.95 <0.01 
Submaximal parameters - -      - - - - - 
GET (L∙min-1)  12 -0.06    0.17 0.11 (0.08-0.16) 11.2 (8.2-17.8) 0.80 <0.01 
MRT (s)  11 25  <0.01 13 (10-21) 49.1 (34.4-89.0) 0.65   0.05 
V̇O2 gain (mL·min
-1
·W
-1
) 12 0.10    0.84 1.18 (0.84-2.01) 17.4 (12.0-31.2) 0.18   0.62 
OUES100  (mL·min
-1
·logL
-1
) 12 -14.12    0.74 100.85 (75.41-156.39) 12.0 (8.9-19.2) 0.79 <0.01 
OUESGET ( mL·min
-1
·logL
-1
) 12 -67.20    0.23 127.89 (95.63-198.31) 17.9 (13.1-39.1) 0.66   0.03 
V̇E/V̇CO2-slope 12 -0.88    0.42 2.54 (1.90-3.94) 7.8 (5.8-12.3) 0.63   0.03 
V̇E/V̇O2 at the GET 12 0.06    0.96 3.19 (2.38-4.94) 10.2 (7.5-16.2) 0.59   0.05 
V̇E/V̇CO2 at the GET 12 1.09    0.32 2.57 (1.92-3.99) 8.8 (6.5-14.0) 0.75   0.01 
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Table 4. Medium-term (4-6 weeks) test-retest reproducibility from baseline (T1-T3) of CPET derived measures.  
 
 
 
 
 
 
Values are reported as means (95% confidence limits). TE, typical error; TECV%, TE expressed as a percentage of the coefficient of variation; ICC, intra-class correlation 
coefficient. See table 2 for list of abbreviations for exercise outcomes. 
 
Variable N Change in 
the mean 
p-value TE (90% CL) TECV% (90% CL) ICC p-value 
Lung function - - - - - - - 
FVC (L) 13 -0.08 0.09 0.11 (0.08-0.16) 3.4 (2.6-5.2) 0.99 <0.01 
FEV1 (L) 13 -0.07 0.07 0.08 (0.06-0.12) 3.4 (2.5-5.1) 0.99 <0.01 
Maximal  exercise parameters - - - - - - - 
V̇O2max (L∙min
-1
) 13 -0.09 0.21 0.16 (0.12-0.25) 13.3 (9.9-20.9) 0.93 <0.01 
HRpeak (b∙min
-1
) 11 -5 0.49 14 (10-22) 7.8 (5.7-12.7) 0.30   0.38 
SaO2 (%) 13 1 0.60 3 (2-5) 3.1 (2.2-5.2) -0.28    0.40 
RPE 13 0.3 0.22 0.6 (0.5-0.9) 7.6 (5.7-11.8) 0.85 <0.01 
RPD 13 0.3 0.68 1.9 (1.4-2.8) 38.5 (27.9-63.8) 0.47   0.13 
Ramp peak power output (W) 13 -12     0.05 14 (11-22) 19.8 (14.7-31.6) 0.95 <0.01 
Submaximal parameters - - - - - - - 
GET (L∙min-1) 12 0.05 0.40 0.14 (0.11-0.22) 16.8 (12.3-27.2) 0.74   0.01 
MRT (s) 11 16 0.12 22 (16-34) 89.0 (60.1-175.8) 0.25    0.48 
V̇O2 gain (mL·min
-1
·W
-1
) 12 -0.28 0.72 1.85 (1.31-3.15) 24.5 (16.8-45.0) 0.24   0.40 
OUES100  (mL·min
-1
·logL
-1
) 12 -4.29 0.92 107.28 (80.21-166.35) 15.3 (11.3-24.7) 0.80 <0.01 
OUESGET ( mL·min
-1
·logL
-1
) 12 -40.69 0.61 188.78 (141.15-292.73) 45.4 (32.3-78.6) 0.69   0.01 
V̇E/V̇CO2-slope 12 -2.00 0.32 4.66 (3.49-7.23) 17.7 (12.9-28.7) 0.13   0.71 
V̇E/V̇O2 at the GET 12 -0.47 0.72 3.13 (2.34-4.86) 10.1 (7.4-16.0) 0.66   0.03 
V̇E/V̇CO2 at the GET 12 -0.12 0.90 2.38 (1.78-3.69) 9.4 (6.9-14.9) 0.79 <0.01 
        
